A Phase 3 interventional study of Placebo and LNP023 in IgA Nephropathy, sponsored by Novartis Pharmaceuticals. Completed at 177 sites in 35 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.
Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 3, and was the 3rd registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States, Brazil, China and 8 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 5 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 8
First in 2018; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 517 is above the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 108 across the 14 interventional studies, 300 across the 3 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Glomerulonephritis, IGA by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06797518Novartis PharmaceuticalsStudy to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | 2027-11-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Glomerulonephritis, IGA by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
The purpose of the study was to evaluate the efficacy and safety of iptacopan (LNP023) compared to placebo on proteinuria reduction and slowing disease progression in primary IgAN patients. This study served as the pivotal trial supporting the registration of iptacopan in IgA Nephropathy patients with the aim to demonstrate a clinically meaningful reduction in in eGFR slope decline and reduction in proteinuria. The trial continued in a blinded fashion to confirm long-term efficacy based on annualized total slope of eGFR decline over 24 months to provide confirmatory evidence of LNP023 efficacy and safety in treating patients with IgAN. The trial planned to enroll approximately 470 participants; 430 biopsy-proven IgAN participants with eGFR ≥30 mL /min/1.73m2 (main study population) and up to approximately 40 participants with eGFR 20 to \<30 mL/min/1.73m2 (severe renal impairment (SRI) population).
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In all cases, if a historical biopsy is not available, one may be performed during screening. *eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local practice guidelines)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LNP023
Drug: Placebo
Placebo to LNP023 200mg b.i.d
LNP023 200mg b.i.d
Also known as: iptacopan
Ratio to Baseline in UPCR at 9 Months - Interim Analysis
Evaluated at interim analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes.
Time frame: Baseline and 9 months
Annualized Total eGFR Slope Estimated Over 24 Months - Final Analysis
Evaluated at final analysis - Annualized total eGFR slope over 24 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function and was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.
Time frame: 24 months
Change From Baseline in eGFR at 9 Months - Interim Analysis
Evaluated at interim analysis - Change from baseline in estimated glomerular filtration rate (eGFR) at 9 months
Time frame: Baseline and 9 months
Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim Analysis
Evaluated at interim analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) sampled from 24-hour urine collection at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.
Time frame: Baseline and 9 months
Annualized Total eGFR Slope Estimated Over 12 Months - Interim Analysis
Evaluated at interim analysis -Annualized total eGFR slope over 12 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.
Time frame: 12 months
Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim Analysis
Evaluated at interim analysis -Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.
Time frame: Baseline and 9 months
Number of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Interim Analysis
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
Time frame: Up to 24 months
Number of Participants With Adverse Events in the SRI Population During the On-treatment Period - Interim Analysis
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
Time frame: Up to 24 months
Ratio to Baseline in UPCR at 9 Months - Final Analysis
Evaluated at final analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes. In line with the testing strategy, this endpoint was not tested at the final analysis.
Time frame: Baseline and 9 months
Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final Analysis
Evaluated at final analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) 24h at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.
Time frame: Baseline and 9 months
Time to First Occurrence of Composite Kidney Failure Endpoint Event - Final Analysis
Evaluated at final analysis - Time to first occurrence of composite kidney failure endpoint, defined as a sustained decline in the eGFR of at least 30% from baseline for at least 4 weeks, a sustained eGFR of less than 15 mL/min/1.73m2 for at least 4 weeks, initiation of maintenance dialysis (defined as dialysis for a period of ≥4 weeks) or death from kidney failure. For clarity: Please note that the number of patients with a composite kidney failure endpoint event is presented with statistical analysis of the time to composite kidney failure endpoint event.
Time frame: Up to 24 months
Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final Analysis
Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.
Time frame: Baseline and Month 9
Number of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Final Analysis
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
Time frame: Up to 24 months
Number of Participants With Adverse Events in the SRI Population During the On-treatment Period- Final Analysis
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
Time frame: Up to 24 months
| Milestone | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Started | 259 | 258 |
| Started - main study population | 238 | 239 |
| Completed study - main study population | 227 | 212 |
| Started - sri population | 21 | 19 |
| Completed study - sri population | 19 | 18 |
| Main population ia-fas | 125 | 125 |
| Main population ia-saf | 222 | 221 |
| Sri population ia-saf | 13 | 14 |
| Sri population saf | 21 | 19 |
| Main population fas | 238 | 239 |
| Main population saf | 238 | 239 |
| Completed | 246 | 230 |
| Not completed | 13 | 28 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Physician decision | 1 | 4 |
| Withdrew: Subject decision | 9 | 21 |
Evaluated at interim analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes.
| ratio | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Ratio to Baseline in UPCR at 9 Months - Interim Analysis | 0.562 (0.491 to 0.642) | 0.910 (0.792 to 1.046) |
Evaluated at final analysis - Annualized total eGFR slope over 24 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function and was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.
| mL/min/1.73m^2/year | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Annualized Total eGFR Slope Estimated Over 24 Months - Final Analysis | -3.100 ± 0.357 | -6.117 ± 0.361 |
Evaluated at interim analysis - Change from baseline in estimated glomerular filtration rate (eGFR) at 9 months
| mL/min/1.73m^2 | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Change From Baseline in eGFR at 9 Months - Interim Analysis | -2.487 (-4.035 to -0.939) | -5.507 (-7.083 to -3.932) |
Evaluated at interim analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) sampled from 24-hour urine collection at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.
| Marginal proportion of participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim Analysis | 0.425 (0.345 to 0.505) | 0.219 (0.148 to 0.290) |
Evaluated at interim analysis -Annualized total eGFR slope over 12 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.
| mL/min/1.73m^2/year | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Annualized Total eGFR Slope Estimated Over 12 Months - Interim Analysis | -4.341 ± 0.730 | -6.944 ± 0.733 |
Evaluated at interim analysis -Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.
| score on a scale | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim Analysis | 0.6 (-0.7 to 1.9) | -0.3 (-1.7 to 1.0) |
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
| Participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Adverse Events (AEs) | 138 | 153 |
| Treatment-related AEs | 26 | 29 |
| Fatal Serious AEs | 0 | 0 |
| Serious AEs | 18 | 11 |
| Treatment -related serious AEs | 5 | 0 |
| AEs leading to discontinuation of treatment | 6 | 6 |
| Severe AEs | 7 | 7 |
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
| Participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Adverse Events (AEs) | 11 | 11 |
| Treatment-related AEs | 2 | 1 |
| Fatal Serious AEs | 0 | 0 |
| Serious AEs | 2 | 2 |
| Treatment-related Serious AEs | 0 | 0 |
| AEs leading to discontinuation of treatment | 1 | 1 |
| Severe AEs | 3 | 2 |
Evaluated at final analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes. In line with the testing strategy, this endpoint was not tested at the final analysis.
| ratio | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Ratio to Baseline in UPCR at 9 Months - Final Analysis | 0.559 (0.514 to 0.607) | 0.918 (0.843 to 0.999) |
Evaluated at final analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) 24h at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.
| Marginal proportion of participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final Analysis | 0.439 (0.380 to 0.498) | 0.175 (0.127 to 0.224) |
Evaluated at final analysis - Time to first occurrence of composite kidney failure endpoint, defined as a sustained decline in the eGFR of at least 30% from baseline for at least 4 weeks, a sustained eGFR of less than 15 mL/min/1.73m2 for at least 4 weeks, initiation of maintenance dialysis (defined as dialysis for a period of ≥4 weeks) or death from kidney failure. For clarity: Please note that the number of patients with a composite kidney failure endpoint event is presented with statistical analysis of the time to composite kidney failure endpoint event.
| Participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Time to First Occurrence of Composite Kidney Failure Endpoint Event - Final Analysis | 51 | 80 |
Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.
| score on a scale | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final Analysis | 1.069 (0.226 to 1.912) | 0.310 (-0.535 to 1.156) |
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
| Participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Adverse Events (AEs) | 207 | 213 |
| Treatment-related AEs | 48 | 49 |
| Fatal Serious AEs | 0 | 0 |
| Serious AEs | 29 | 28 |
| Treatment-related serious AEs | 9 | 2 |
| AEs leading to discontinuation of treatment | 11 | 11 |
| Treatment-related AEs leading to discontinuation of treatment | 5 | 0 |
| Severe AEs | 15 | 18 |
| Treatment-related severe AEs | 4 | 2 |
Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment
| Participants | LNP023 200mg b.i.d | Placebo |
|---|---|---|
| Adverse Events (AEs) | 18 | 17 |
| Treatment-related AEs | 3 | 2 |
| Fatal Serious AEs | 0 | 0 |
| Serious AEs | 4 | 2 |
| Treatment-related Serious AEs | 1 | 0 |
| AEs leading to discontinuation of treatment | 1 | 1 |
| Treatment-related AEs leading to discontinuation of treatment | 0 | 0 |
| Severe AEs | 3 | 2 |
| Treatment-related Severe AEs | 1 | 0 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 25 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| On-trt LNP023 200mg b.i.d. Main | 0/238 (0%) | 29/238 (12.2%) | 168/238 (70.6%) |
| On-trt Placebo Main | 0/239 (0%) | 28/239 (11.7%) | 173/239 (72.4%) |
| On-trt All Participants Main | 0/477 (0%) | 57/477 (11.9%) | 341/477 (71.5%) |
| On-trt LNP023 200mg b.i.d. SRI | 0/21 (0%) | 4/21 (19%) | 15/21 (71.4%) |
| On-trt Placebo SRI | 0/19 (0%) | 2/19 (10.5%) | 17/19 (89.5%) |
| On-trt All Participants SRI | 0/40 (0%) | 6/40 (15%) | 32/40 (80%) |
| Post-trt LNP023 200mg b.i.d. Main | 0/238 (0%) | 9/238 (3.8%) | 16/238 (6.7%) |
| Post-trt Placebo Main | 0/239 (0%) | 9/239 (3.8%) | 29/239 (12.1%) |
| Post-trt All Participants Main | 0/477 (0%) | 18/477 (3.8%) | 45/477 (9.4%) |
| Post-trt LNP023 200mg b.i.d. SRI | 0/21 (0%) | 2/21 (9.5%) | 4/21 (19%) |
| Post-trt Placebo SRI | 0/19 (0%) | 3/19 (15.8%) | 5/19 (26.3%) |
| Post-trt All Participants SRI | 0/40 (0%) | 5/40 (12.5%) | 9/40 (22.5%) |
| Event | On-trt LNP023 200mg b.i.d. Main | On-trt Placebo Main | On-trt All Participants Main | On-trt LNP023 200mg b.i.d. SRI | On-trt Placebo SRI | On-trt All Participants SRI | Post-trt LNP023 200mg b.i.d. Main | Post-trt Placebo Main | Post-trt All Participants Main | Post-trt LNP023 200mg b.i.d. SRI | Post-trt Placebo SRI | Post-trt All Participants SRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/238 | 0/239 | 1/477 | 0/21 | 0/19 | 0/40 | 0/238 | 0/239 | 0/477 | 0/21 | 1/19 | 1/40 |
| International normalised ratio increasedInvestigations | 0/238 | 0/239 | 0/477 | 0/21 | 1/19 | 1/40 | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/238 | 0/239 | 0/477 | 0/21 | 1/19 | 1/40 | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 |
| Acute kidney injuryRenal and urinary disorders | 4/238 | 2/239 | 6/477 | 0/21 | 1/19 | 1/40 | 1/238 | 1/239 | 2/477 | 0/21 | 0/19 | 0/40 |
| Chronic kidney diseaseRenal and urinary disorders | 0/238 | 1/239 | 1/477 | 0/21 | 1/19 | 1/40 | 0/238 | 3/239 | 3/477 | 1/21 | 0/19 | 1/40 |
| End stage renal diseaseRenal and urinary disorders | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 | 0/238 | 0/239 | 0/477 | 0/21 | 1/19 | 1/40 |
| Renal failureRenal and urinary disorders | 0/238 | 0/239 | 0/477 | 1/21 | 0/19 | 1/40 | 0/238 | 2/239 | 2/477 | 0/21 | 1/19 | 1/40 |
| HypertensionVascular disorders | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 | 0/238 | 0/239 | 0/477 | 0/21 | 1/19 | 1/40 |
| PneumoniaInfections and infestations | 4/238 | 1/239 | 5/477 | 1/21 | 0/19 | 1/40 | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 |
| Pneumonia bacterialInfections and infestations | 1/238 | 1/239 | 2/477 | 1/21 | 0/19 | 1/40 | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 |
| Event | On-trt LNP023 200mg b.i.d. Main | On-trt Placebo Main | On-trt All Participants Main | On-trt LNP023 200mg b.i.d. SRI | On-trt Placebo SRI | On-trt All Participants SRI | Post-trt LNP023 200mg b.i.d. Main | Post-trt Placebo Main | Post-trt All Participants Main | Post-trt LNP023 200mg b.i.d. SRI | Post-trt Placebo SRI | Post-trt All Participants SRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 49/238 | 47/239 | 96/477 | 4/21 | 6/19 | 10/40 | 0/238 | 5/239 | 5/477 | 1/21 | 0/19 | 1/40 |
| HyperkalaemiaMetabolism and nutrition disorders | 10/238 | 18/239 | 28/477 | 2/21 | 5/19 | 7/40 | 1/238 | 3/239 | 4/477 | 1/21 | 1/19 | 2/40 |
| Upper respiratory tract infectionInfections and infestations | 38/238 | 37/239 | 75/477 | 0/21 | 0/19 | 0/40 | 1/238 | 5/239 | 6/477 | 0/21 | 0/19 | 0/40 |
| HypertensionVascular disorders | 6/238 | 24/239 | 30/477 | 2/21 | 3/19 | 5/40 | 1/238 | 0/239 | 1/477 | 2/21 | 0/19 | 2/40 |
| InfluenzaInfections and infestations | 11/238 | 10/239 | 21/477 | 3/21 | 1/19 | 4/40 | 0/238 | 1/239 | 1/477 | 0/21 | 0/19 | 0/40 |
| HyperlipidaemiaMetabolism and nutrition disorders | 13/238 | 16/239 | 29/477 | 3/21 | 0/19 | 3/40 | 0/238 | 0/239 | 0/477 | 0/21 | 0/19 | 0/40 |
| NasopharyngitisInfections and infestations | 24/238 | 29/239 | 53/477 | 1/21 | 0/19 | 1/40 | 2/238 | 2/239 | 4/477 | 1/21 | 0/19 | 1/40 |
| DiarrhoeaGastrointestinal disorders | 14/238 | 13/239 | 27/477 | 2/21 | 1/19 | 3/40 | 0/238 | 2/239 | 2/477 | 0/21 | 2/19 | 2/40 |
| Chest painGeneral disorders and administration site conditions | 4/238 | 5/239 | 9/477 | 0/21 | 2/19 | 2/40 | 1/238 | 0/239 | 1/477 | 0/21 | 0/19 | 0/40 |
| Urinary tract infectionInfections and infestations | 6/238 | 11/239 | 17/477 | 1/21 | 0/19 | 1/40 | 0/238 | 0/239 | 0/477 | 0/21 | 2/19 | 2/40 |
| Age, Categorical(Participants) | LNP023 200mg b.i.d | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 254 | 248 | 502 |
| >=65 years | 5 | 10 | 15 |
| Age, Continuous(years) | LNP023 200mg b.i.d | Placebo | Total |
|---|---|---|---|
| Mean | 40.0 ± 11.52 | 39.6 ± 12.48 | 39.8 ± 12.00 |
| Sex: Female, Male(Participants) | LNP023 200mg b.i.d | Placebo | Total |
|---|---|---|---|
| Female | 111 | 126 | 237 |
| Male | 148 | 132 | 280 |
| Race/Ethnicity, Customized(Participants) | LNP023 200mg b.i.d | Placebo | Total |
|---|---|---|---|
| Race — White | 127 | 125 | 252 |
| Race — Black/African American | 0 | 4 | 4 |
| Race — Asian | 129 | 126 | 255 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Race — American Indian or Alaska Native | 2 | 2 | 4 |
Showing the first 100 of 177 sites across 35 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2021 to primary completion in Sep 2025, 55 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 55 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iptacopan